# Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

> **NCT04091646** · PHASE2 · COMPLETED · sponsor: **Arcutis Biotherapeutics, Inc.** · enrollment: 226 (actual)

## Conditions studied

- Seborrheic Dermatitis

## Interventions

- **DRUG:** Roflumilast Foam 0.3%
- **DRUG:** Vehicle foam

## Key facts

- **NCT ID:** NCT04091646
- **Lead sponsor:** Arcutis Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-04
- **Primary completion:** 2020-08-18
- **Final completion:** 2020-08-21
- **Target enrollment:** 226 (ACTUAL)
- **Last updated:** 2023-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04091646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04091646, "Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04091646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*